PHARMACY

FDA approves Marillion NDA for novel cancer treatment

BY Drew Buono

MALVERN, Pa. Marillion Pharmaceuticals has received approval from the Food and Drug Administration for it investigational new drug application for its lead product candidate MN-201, a vitamin D5 analog for the treatment of cancer.

The drug will now proceed to Phase 1 human clinical trial for patients with advanced tumors in various cancers.

In preclinical studies, MN-201 performed well against cancer cells. In animal models, MN-201 also resulted in anti-tumor activity including tumor regression in xenograft models of major solid tumor types. In contrast to treatment with other vitamin D(3) analogs and the naturally occurring vitamin D hormone, calcitriol, favorable anticancer effects with MN-201 were observed in the absence of significantly raised calcium levels.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Pharma, biotech companies in line of wildfires

BY Drew Buono

SAN DIEGO With the wildfires still blazing in areas across San Diego, such pharma and biotech companies as Pfizer are preparing for closures and even evacuations of some of their facilities, according to drugresearcher.com.

Pfizer’s La Jolla research and development site is a 33.5-acre campus, with facilities covering more than 1 million square feet, including  Pfizer’s vaccines research and The Pfizer Incubator, a new facility where the company is financing life science start-ups.  The HIV drug Viracept is produced at the site, as well as new treatments for cancer and diseases of the eye.

Across San Diego County, there are more than 500 life science companies employing more than 36,000 people, according to industry association Biocom.  The companies range from small biotechs to some of the biggest names in drug development, such as Johnson & Johnson, Bristol-Myers Squibb, Amgen, Biogen Idec, Genentech and Pfizer.  Between them, they generate more than $23 million for the economy every day.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Pharmacy OneSource ranks in Deloitte’s top 100

BY Drew Buono

BELLEVUE, Wash. Pharmacy OneSource has been ranked number 84 on Deloitte’s Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. The company grew 2011 percent in fiscal revenue from 2002-2006, which was the time period used to measure each company’s ranking.

“We enjoy our strong relationship with pharmacy professionals and the opportunity it brings to stay intimate with their needs,” said Keith Streckenbach, chief strategy officer. “This knowledge, combined with excellent hires, has catalyzed our growth.”

Pharmacy OneSource was also ranked sixth on the Washington State Technology Fast 50, which ranks the 50 fastest growing technology firms in Washington State.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES